Source-grounded facts extracted from Vivos Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Roman Franklin was appointed as Chief Financial Officer at Vivos Therapeutics, Inc..
“Effective July 31, 2026, the Board appointed Roman Franklin, age 42, as the Company’s Chief Financial Officer, and designated Mr. Franklin as the Company’s principal financial officer for purposes of the Securities Exchange Act of 1934, as amended.”
Bradford Amman resigned as Chief Financial Officer and Secretary at Vivos Therapeutics, Inc..
“On July 31, 2026, Bradford Amman resigned as Chief Financial Officer and Secretary of the Company, and from all other officer and committee positions held by reason of his employment, effective as of that date.”
Vivos Therapeutics, Inc. entered into Collaboration Agreement with South Palm Cardiovascular Associates, LLC valued at Formation of new management services organization AIM Florida, LLC; Vivos holds not less than 80% me (effective 2026-06-10).
“On June 10, 2026, Vivos Therapeutics, Inc. (the “Company”) entered into a Collaboration Agreement (the “Collaboration Agreement”) with South Palm Cardiovascular Associates, LLC, a Florida limited liability company (“SPCVA”), pursuant to which the parties agreed to collaborate in the formation and operation of a new management services organization to be known as AIM Florida, LLC (“AIM Florida”). AIM Florida is intended to provide administrative, operational, billing, payer-contracting, marketing, platform, data and other non-clinical support services to one or more affiliated professional clinical entities that will deliver sleep apnea diagnostic and treatment services to patients, with the collaboration initially focused on the Palm Beach County, Florida market. Under the Collaboration Agreement, the Company expects to hold not less than 80% of the membership interests in AIM Florida, and SPCVA expects to hold up to 20% of the membership interests, in each case subject to the negotiat”
Vivos Therapeutics, Inc. incurred convertible notes of maximum principal amount of up to $5,000,000 with V-Co Investors 4 LLC at does not bear any interest.
“On May 7, 2026, the Company entered into an unsecured convertible promissory note in favor of V-Co Investors 4 LLC (“ V-Co 4 ”) in the maximum principal amount of up to $5,000,000”
Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“June 5, 2026, the Company received a letter from the Listing Qualifications Staff of Nasdaq indicating that, based upon the closing bid price of the Common Stock, from April 23, 2026 to June 4, 2026, the Company is no longer in compliance with the requirement for continued listing on The Nasdaq Capital Market to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “ Notice ”). The Notice has no immediate effect on the continued listing status of the Company’s Common Stock on The Nasdaq Capital Market, and, therefore, the Company’s listing remains”
Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“April 17, 2026, Vivos Therapeutics, Inc. (the “Company”) received a letter (“Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s stockholde”
Vivos Therapeutics, Inc. reported the full year ended December 31, 2025 results: revenue $17.5 million.
“Revenue was $17.5 million for the year ended December 31, 2025, compared to $15.0 million for the full year ended December 31, 2024, a year over year increase of 16%.”
Vivos Therapeutics, Inc. issued a pre-funded warrant to purchase 429,957 shares of Common Stock (the " Pre-Funded Warrant "), (iii) a Series A Common Stock Purchase Warrant (the " Series A War of warrant to V-Co Investors 3 LLC for purchase price of $1.34 for each PIPE Share and Pre-Funded Warrant Share and associated Common Stock Purchase Warrants.
““ Warrants ”, and with the shares of Common Stock underlying the Common Stock Purchase Warrants being referred to as the “ Warrant Shares ”). V-Co 3 paid a purchase price of $1.34 for each PIPE Share and Pre-Funded Warrant Share and associated Common Stock Purchase Warrants, with such price being established for purposes of compliance with the listing rules”
Vivos Therapeutics, Inc. issued 1,353,625 shares (the "PIPE Shares") of Common Stock of common stock to V-Co Investors 3 LLC for purchase price of $1.34 for each PIPE Share and Pre-Funded Warrant Share and associated Common Stock Purchase Warrants.
““ Warrants ”, and with the shares of Common Stock underlying the Common Stock Purchase Warrants being referred to as the “ Warrant Shares ”). V-Co 3 paid a purchase price of $1.34 for each PIPE Share and Pre-Funded Warrant Share and associated Common Stock Purchase Warrants, with such price being established for purposes of compliance with the listing rules”
Vivos Therapeutics, Inc. entered into Securities Purchase Agreement with V-Co Investors 3 LLC valued at $850,000 cash proceeds; $1,400,000 conversion of bridge note; total purchase price $1.34 per share (effective 2026-03-31).
“On March 31, 2026, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a Securities Purchase Agreement (the “ PIPE SPA ”) with V-Co Investors 3 LLC, a Wyoming limited liability company (“ V-Co 3 ”).”
Vivos Therapeutics, Inc. issued 138,765 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC.
“issued to Wainwright or its designees warrants to purchase 138,765 shares of Common Stock representing 7.0% of the shares of Common Stock underlying the Inducement Warrants”
Vivos Therapeutics, Inc. issued up to 1,982,356 shares of Common Stock of warrant to an institutional investor.
“a five-year, Series A Common Stock Purchase Warrant to purchase up to 1,982,356 shares of Common Stock at an exercise price of $2.09 per share”
Vivos Therapeutics, Inc. entered into Warrant Inducement Letter Agreement with an institutional investor valued at The Company agreed to issue warrants to purchase up to 3,964,712 shares of Common Stock at an exerci (effective 2026-01-15).
“On January 15, 2026, the Company entered into a warrant inducement letter agreement with the Holder (the “ Inducement Agreement ”) pursuant to which the Holder agreed to exercise for cash the entirety of the Warrants at a reduced exercise price of $2.34 per share (with such exercise price being established for purposes of compliance with the listing rules of the Nasdaq Stock Market), resulting in gross proceeds to the Company of approximately $4.6 million.”
Vivos Therapeutics, Inc. entered into Note with V-Co Investors 3 LLC valued at up to $5,500,000 (effective 2026-01-15).
“On January 15, 2026, Vivos Therapeutics, Inc. (the “ Company ”) entered into an unsecured convertible promissory note in favor of V-Co Investors 3 LLC (“ V-Co ”) in the maximum principal amount of up to $5,500,000 (the “ Note ” and the maximum principal amount, inclusive of the original issuance discount described below, the “ Maximum Principal ”).”
Vivos Therapeutics, Inc. entered into Note Purchase Agreement with Avondale Capital, LLC valued at $2,093,340 (effective 2025-12-05).
“On December 5, 2025, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into a Note Purchase Agreement (the “ Note Purchase Agreement ”) with from Avondale Capital, LLC, a Utah limited liability company (" Lender "), pursuant to which the Company issued and sold to Lender a Promissory Note (the “ Note ”) in the original principal amount of $2,093,340”
Vivos Therapeutics, Inc. incurred loan of $2,093,340 with Avondale Capital, LLC at does not bear interest maturing not stated.
“On December 5, 2025, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into a Note Purchase Agreement (the “ Note Purchase Agreement ”) with from Avondale Capital, LLC, a Utah limited liability company (“ Lender ”), pursuant to which the Company issued and sold to Lender a Promissory Note (the “ Note ”) in the original principal amount of $2,093,340”
Vivos Therapeutics, Inc. completed an acquisition involving The Sleep Center of Nevada (SCN) (closed 2025-06-10).
“On June 10, 2025, the Company completed the Acquisition, and the Company had acquired all of the operating assets of the Seller in consideration for a (i) cash payment equal to $6.0 million, (ii) 607,287 shares of restricted common stock in the Company, par value $0.0001 per share (the “ Common Stock ”), equal to $1.5 million based on the volume-weighted average price (“ VWAP ”) of the Common Stock for the 30 days immediately preceding the Acquisition and (iii) the assumption of certain specific trade accounts payable and liabilities related to specific SCN contracts assigned to the Company as part of the Acquisition.”
Vivos Therapeutics, Inc. engaged Baker Tilly US, LLP as its auditor.
“the Audit Committee of the Company’s Board of Directors approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company’s independent registered public accounting firm”
Moss Adams LLP resigned as auditor of Vivos Therapeutics, Inc..
“(the “Company”) was formally notified that Moss Adams LLP (“Moss Adams”), the Company’s independent registered public accounting firm, merged with Baker Tilly US, LLP effective on June 3, 2025.”
Vivos Therapeutics, Inc. incurred convertible notes of $1,100,000 with V-Co Investors 2 LLC at 0% (15% per annum upon Event of Default) maturing No fixed maturity date; convertible prior to Outside Date or repayable after Outside Date.
“On May 21, 2025, Vivos Therapeutics, Inc. (the “ Company ”) entered into a convertible promissory note in favor of V-Co Investors 2 LLC (“ V-Co ”) in the principal amount of $1,100,000 (the “ Note ”).”
Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“rch 31, 2024) being less than $2.5 million. The Notice also indicated that Nasdaq would commence delisting proceedings against the Company. The Company has the right to, and has already filed for, an appeal the Nasdaq staff’s determination, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series, to request an additional hearing on this matter before the Hearing Panel. The Company’s appeal has stayed any delisting or suspension action by the Nasdaq staff pending the issuance of the Hearing’s Panel decision. The Company’s common stock will remain listed on Nasdaq, pending th”
Vivos Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $3.4 million.
“Revenue was $3.4 million for the first quarter of 2024, compared to $3.8 million for the first quarter of 2023”
Vivos Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2023.
“On March 28, 2024, Vivos Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.”
Vivos Therapeutics, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners (effective 2023-10-30).
“Pursuant to a placement agency agreement dated October 30, 2023, between the Company and the Placement Agent (the “ Placement Agency Agreement ”), the Company agreed to pay to the Placement Agent a cash fee equal to 7.0% of the gross proceeds received by the Company in the Private Placement”
Vivos Therapeutics, Inc. entered into Registration Rights Agreement with the Purchaser (effective 2023-11-02).
“On the Closing Date, in connection with the Private Placement, the Company entered into a registration rights agreement with the Purchaser (the “ Registration Rights Agreement ”), pursuant to which the Company agreed to file a registration statement with the Securities and Exchange Commission (the “ SEC ”) covering the resale of the Shares and the shares of Common Stock issuable upon exercise of the Warrants within 20 days of the Closing Date”
Vivos Therapeutics, Inc. amended January 2023 Warrant Amendment with the Purchaser (effective 2023-11-02).
“Such amendment (the “ January 2023 Warrant Amendment ”), which became effective upon the closing of the Private Placement, reduced the exercise price of the January 2023 Warrant to $3.83 per share and extended the expiration date of the January 2023 Warrant to November 2, 2028.”
Vivos Therapeutics, Inc. entered into Securities Purchase Agreement with an institutional investor valued at $4,000,003.44 (effective 2023-10-30).
“On October 30, 2023, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with an institutional investor (the “ Purchaser ”) pursuant to which the Company agreed sell an aggregate of $4,000,003.44 of securities of the Company in a private placement”
Vivos Therapeutics, Inc.: Amended certificate of incorporation to effect a 1-for-25 reverse stock split (effective 2023-10-25).
“On October 25, 2023, Vivos Therapeutics, Inc. (the “ Company ”) filed a Certificate of Amendment to the Company’s Certificate of Incorporation with the Secretary of State of Delaware (the “ Certificate of Amendment ”) to effectuate a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “ Common Stock ”) at a ratio of 1-for-25 (the “ Reverse Stock Split ”).”
Vivos Therapeutics, Inc. shareholders approved Amendment to Certificate of Incorporation to effect a reverse stock split at a ratio of between one-for-ten and one-for-thirty, with ratio to be determined by Board at the 2023-09-22 meeting.
“Proposal No. 4 – Approval of Reverse Stock Split An amendment to the Company’s Certificate of Incorporation, as amended to effect a Reverse Split at a ratio of between one-for-ten and one-for-thirty, with such ratio to be determined at the sole discretion of the Company’s Board of Directors, was approved.”
Vivos Therapeutics, Inc. shareholders approved Ratification of appointment of Moss Adams LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-09-22 meeting.
“Proposal No. 3 – Ratification of the appointment of independent registered public accounting firm Appointment by the Company’s audit committee of Moss Adams LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified.”
Vivos Therapeutics, Inc. shareholders approved Election of six directors for a one-year term at the 2023-09-22 meeting.
“Proposal No. 2 – Election of Directors Dr. Ralph Green, Anja Krammer, Mark Lindsay, Leonard Sokolow, Dr. Matthew Thompson and R. Kirk Huntsman were each elected as a director to serve for a one-year term that expires at the 2024 annual meeting of stockholders or until a successor is elected and qualified or until her or his earlier death, incapacity, removal or resignation.”
Vivos Therapeutics, Inc. shareholders approved Amendment to Amended and Restated 2019 Stock Option and Stock Issuance Plan to increase authorized shares by 2,000,000 at the 2023-09-22 meeting.
“Proposal No. 1 – Amendment to 2019 Plan An amendment to the Company’s 2019 Plan to increase the number of shares of Company common stock authorized to be issued pursuant to the 2019 Plan by 2,000,000 shares from an aggregate of 2,366,667 shares to an aggregate of 4,366,667 shares was approved.”
Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“August 17, 2023, the Company received a staff deficiency notice from Nasdaq indicating that the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023 did not satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1), which requires that a listed company’s stockholders’ equity be at least $2,500,000 (the “Minimum Stockholders’ Equity Requirement”). On September 21, 2023, the Company received a written notice (the “Notice”) from the Nasdaq staff confirming the staff’s determination that the Company had, a”
Vivos Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“September 21, 2023, the Company received a written notice (the “Notice”) from the Nasdaq staff confirming the staff’s determination that the Company had, as of the date of the Notice, failed to meet the Minimum Bid Requirement and that Nasdaq would commence delisting proceedings against the Company. The Company may appeal the Nasdaq staff’s determination, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series, no later than 4:00 pm Eastern Time on September 28, 2023. The Company plans to timely file such an appeal and request a hearing (the “Hearing”) before a Nasdaq Heari”
Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“be at least $2,500,000 (the “Minimum Stockholders’ Equity Requirement”). As reported in its Form 10-Q, the Company’s stockholders’ equity as of June 30, 2023 was approximately $2,106,000. The Staff’s notice has no immediate impact on the listing of the Company’s common stock on Nasdaq. In accordance with the Nasdaq Listing Rules, the Company has 45 calendar days,”
Vivos Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $3.4 million.
“reported financial results and operating highlights for the second quarter and six months ended June 30, 2023. Second Quarter 2023 Financial and Operating Summary ● Revenue was $3.4 million for the second quarter of 2023 and $7.3 million for the six months ended June 30, 2023, compared to $4.2 million and $7.8 million for the three and six months ended June 30,”
Vivos Therapeutics, Inc. reported first quarter ended March 31, 2023 results: revenue $3.9 million.
“Revenue was $3.9 million for the first quarter of 2023”
Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“May 23, 2023, Vivos Therapeutics, Inc. (the “ Company ”) received a staff deficiency notice from The Nasdaq Stock Market (“ Nasdaq ”) indicating that, because Nasdaq has not yet received the Company’s Form 10-Q for the quarter ended March 31, 2023, the Company no longer complies with the Nasdaq Listing Rules for continued listing under Rule 5250(c)(1) (the “ Periodic Filing Requirement ”). Nasdaq’s notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. The Company’s failure to file its Form 10-Q for the quarter ended March 31, 2023 is consider”
Vivos Therapeutics, Inc. engaged Moss Adams LLP as its auditor.
“ay 3, 2023, the Committee approved the engagement of Moss Adams LLP (“ Moss Adams ”) as the Company’s new independent registered public accounting firm, effective immediately.”
Vivos Therapeutics, Inc. dismissed Plante & Moran, PLLC as its auditor.
“(the “ Company ”) dismissed Plante & Moran, PLLC (“ P&M ”), the Company’s independent registered public accounting firm, effective immediately.”
Vivos Therapeutics, Inc. reported fourth quarter and fiscal year ended December 31, 2022 results: revenue $4.0 million for the fourth quarter of 2022 and $16.0 million for the full year ended December 31, 2022.
“On March 30, 2023, Vivos Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022.”
Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“March 24, 2023, Vivos Therapeutics, Inc. (the “Company”) received a staff deficiency notice from The Nasdaq Stock Market (“Nasdaq”) indicating that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days (February 9, 2023 through March 23, 2023), the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Rule 5550(a)(2) of the Nasdaq Listing Rules. Nasdaq’s notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Ma”
Vivos Therapeutics, Inc. entered into Placement Agency Agreement with Roth Capital Partners, LLC and A.G.P./Alliance Global Partners valued at cash fee equal to 6.0% of the gross proceeds received by the Company in the Private Placement, in ad (effective 2023-01-05).
“Pursuant to a placement agency agreement, dated January 5, 2023, between the Company and the Placement Agents (the “Placement Agency Agreement”), the Company agreed to pay the Placement Agent a cash fee equal to 6.0% of the gross proceeds received by the Company in the Private Placement, in addition to the reimbursement of $40,000 of expenses.”
Vivos Therapeutics, Inc. entered into Registration Rights Agreement with institutional investor valued at file a registration statement with the SEC to register for resale the Shares and the shares of Commo (effective 2023-01-05).
“On January 5, 2023, in connection with the Private Placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchaser, pursuant to which the Company agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) to register for resale the Shares and the shares of Common Stock issuable upon exercise of the Warrants within 30 days of the signing of the Registration Rights Agreement, with such registration statement to be effective by February 14, 2023 (if such registration statement is not subject to review by the SEC) or within 75 days after the signing of the Registration Rights Agreement (if such registration statement is subject to limited or full review by the SEC).”
Vivos Therapeutics, Inc. entered into Securities Purchase Agreement with institutional investor valued at up to an aggregate of $8,000,000 of securities (effective 2023-01-05).
“On January 5, 2023, Vivos Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (“Purchase Agreement”) with an institutional investor (the “Purchaser”) pursuant to which the Company agreed sell up to an aggregate of $8,000,000 of securities of the Company in a private placement (the “Private Placement”) of units.”
Vivos Therapeutics, Inc. reported the third quarter of 2022 results: revenue $4.2 million.
“Revenue was $4.2 million for the third quarter of 2022 and $12.1 million for the nine months ended September 30, 2022, compared to $4.5 million and $12.5 million for the three and nine months ended September 30, 2021, respectively, which similarly in part reflects a deferral of a portion of revenue into future periods under Vivos’ new revenue recognition policies;”
Vivos Therapeutics, Inc. reported the second quarter of 2022 results: revenue $4.2 million.
“Revenue was $4.2 million for the second quarter of 2022 and $7.8 million for the six months ended June 30, 2022, compared to $4.5 million and $7.9 million for the three and six months ended June 30, 2021, respectively, which in part reflects a deferral of a portion of revenue into future periods under Vivos’ new revenue recognition policies;”
Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“November 16, 2022, Vivos Therapeutics, Inc. (the “Company”) received a staff deficiency notice from The Nasdaq Stock Market (“Nasdaq”) indicating that, because Nasdaq has not yet received the Company’s Form 10-Q for the quarter ended September 30, 2022, the Company no longer complies with the Nasdaq Listing Rules for continued listing under Rule 5250(c)(1) (the “Periodic Filing Requirement”). Nasdaq’s notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. As reported in a press release dated August 26, 2022, the Company previously received a d”
Vivos Therapeutics, Inc. reported that prior financial statements should not be relied upon.
“the Company’s previously issued unaudited interim consolidated financial statements for the Restated Period included in its Quarterly Report on Form 10-Q for the Restated Period, as originally filed with the Securities and Exchange Commission on May 16, 2022, should no longer be relied upon.”
Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“November 3, 2022, Vivos Therapeutics, Inc. (the “Company”) received a staff deficiency notice from The Nasdaq Stock Market (“Nasdaq”) indicating that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days (September 22, 2022 through November 2, 2022), the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Rule 5550(a)(2) of the Nasdaq Listing Rules. Nasdaq’s notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capi”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.